Karyopharm Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
KPTI$0.02-56.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
| Common Shares · AdditionalPaid-InCapital · AccumulatedOtherComprehensive (Loss)Income · AccumulatedDeficit · TotalStockholders’Deficit | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at March 31, 2024 | 116,457 | $12 | $1,355,951 | $(518) | $(1,524,400) | $(168,955) |
| Vesting of restricted stock | 151 | — | — | — | — | — |
| Shares issued under the employee stock purchase plan | 1,155 | — | 772 | — | — | 772 |
| Issuance of common stock for financial advisory fee | 6,872 | 1 | 6,927 | — | — | 6,928 |
| Stock-based compensation | — | — | 5,410 | — | — | 5,410 |
| Unrealized loss on investments | — | — | — | (10) | — | (10) |
| Foreign currency cumulative translation adjustment | — | — | — | (77) | — | (77) |
| Net income | — | — | — | — | 23,792 | 23,792 |
| Balance at June 30, 2024 | 124,635 | $13 | $1,369,060 | $(605) | $(1,500,608) | $(132,140) |
| Balance at March 31, 2023 | 113,971 | $12 | $1,333,298 | $(419) | $(1,378,065) | $(45,174) |
| Vesting of restricted stock | 78 | — | — | — | — | — |
| Exercise of stock options and shares issued under the employee stock purchase plan | 291 | — | 860 | — | — | 860 |
| Stock-based compensation expense | — | — | 6,060 | — | — | 6,060 |
| Unrealized loss on investments | — | — | — | (297) | — | (297) |
| Foreign currency cumulative translation adjustment | — | — | — | (67) | — | (67) |
| Net loss | — | — | — | — | (32,630) | (32,630) |
| Balance at June 30, 2023 | 114,340 | $12 | $1,340,218 | $(783) | $(1,410,695) | $(71,248) |
| Balance at December 31, 2023 | 114,915 | $12 | $1,350,981 | $(161) | $(1,487,038) | $(136,206) |
| Vesting of restricted stock | 1,693 | — | — | — | — | — |
| Shares issued under the employee stock purchase plan | 1,155 | — | 772 | — | — | 772 |
| Issuance of common stock for financial advisory fee | 6,872 | 1 | 6,927 | — | — | 6,928 |
| Stock-based compensation | — | — | 10,380 | — | — | 10,380 |
| Unrealized loss on investments | — | — | — | (49) | — | (49) |
| Foreign currency cumulative translation adjustment | — | — | — | (395) | — | (395) |
| Net loss | — | — | — | — | (13,570) | (13,570) |
| Balance at June 30, 2024 | 124,635 | $13 | $1,369,060 | $(605) | $(1,500,608) | $(132,140) |
| Balance at December 31, 2022 | 113,213 | $12 | $1,327,909 | $(638) | $(1,343,939) | $(16,656) |
| Vesting of restricted stock | 836 | — | — | — | — | — |
| Exercise of stock options and shares issued under the employee stock purchase plan | 291 | — | 860 | — | — | 860 |
| Stock-based compensation expense | — | — | 11,449 | — | — | 11,449 |
| Unrealized loss on investments | — | — | — | (264) | — | (264) |
| Foreign currency cumulative translation adjustment | — | — | — | 119 | — | 119 |
| Net loss | — | — | — | — | (66,756) | (66,756) |
| Balance at June 30, 2023 | 114,340 | $12 | $1,340,218 | $(783) | $(1,410,695) | $(71,248) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.